← All trials
NCT05601492
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Feb 29, 2024
- First posted
- Nov 1, 2022
- Last posted
- Nov 29, 2022
- Enrollment
- 84
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wake Forest UniversityLead sponsor
- AmgenCollaborator
- Wake Forest UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.